Opinion

Video

Data Surrounding Treatment for MSI-high Patients from ASCO 2024

Dr Kim offers key perspective for MSI-high patients based on data presented at ASCO 2024.

Related Videos
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, discuss factors that influence later-line treatment choices in chronic myeloid leukemia.
Javier Pinilla, MD, PhD, and Talha Badar, MBBS, MD, on the implications of the FDA approval of asciminib in newly diagnosed CP-CML.
Andrew Kuykendall, MD
Prithviraj Bose, MD, and Chandler Park, MD, FACP
Peter Forsyth, MD
Richard Kim, MD, Moffitt Cancer Center